Masanori Wakisaka
Fukuoka, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
The presence of sodium glucose co-transporter 2 in mesangial cells and pericytes and its roles in mesangial lesions and in capillaries under diabetic and ischemic conditions.
Journal: Diabetes research and clinical practice
Published: August 27, 2022
Low-dose sodium-glucose cotransporter 2 inhibitor ameliorates ischemic brain injury in mice through pericyte protection without glucose-lowering effects.
Journal: Communications biology
Published: August 15, 2021
Roles of Sodium-Glucose Cotransporter 2 of Mesangial Cells in Diabetic Kidney Disease.
Journal: Journal of the Endocrine Society
Published: January 13, 2021
Lessons from the Trials for the Desirable Effects of Sodium Glucose Co-Transporter 2 Inhibitors on Diabetic Cardiovascular Events and Renal Dysfunction.
Journal: International journal of molecular sciences
Published: October 21, 2019
Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells.
Journal: Scientific reports
Published: September 26, 2018
Recovery from Diabetic Macular Edema in a Diabetic Patient After Minimal Dose of a Sodium Glucose Co-Transporter 2 Inhibitor.
Journal: The American journal of case reports
Published: April 20, 2018
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Journal: The New England journal of medicine
Published: November 03, 2016
Sodium Glucose Cotransporter 2 (SGLT2) Plays as a Physiological Glucose Sensor and Regulates Cellular Contractility in Rat Mesangial Cells.
Journal: PloS one
Published: January 01, 2016
Showing 1-9 of 9
Last Updated: 09/26/2026